• DOI:10.1002/BDRB.20000
Corpus ID: 23081098

Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.

@article{Crofts2004CriticalPF,
  title={Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.},
  author={F. Crofts and S. Rohatagi and M. Pino and B. DeLise and J. Zhang and M. Nguyen and P. Guittin and S. Barbellion and P. Brunel and T. Hofmann and J. Schmidt and M. Wong and P. Lockey and S. Lerman and R. Clark},
  journal={Birth defects research. Part B, Developmental and reproductive toxicology},
  year={2004},
  volume={71 2},
  pages={
          69-79
        }
}

• F. Crofts, S. Rohatagi, +12 authors R. Clark
• Published 2004
• Biology, Medicine
• Birth defects research. Part B, Developmental and reproductive toxicology

BACKGROUND Integrins such as VLA-4 (Very late antigen 4, integrin alpha4beta1) play key roles in cell-cell interactions that are critical for development. Homozygous null knockouts of the VLA-4 alpha4-subunit or VCAM-1 (VLA-4 cell surface ligand) in mice result in failure of the allantois and chorion to fuse leading to interrupted placentation and cardiac development and embryo lethality. Embryo-fetal studies of three VLA-4 antagonists, IVL745, IVL984, and HMR1031 [Crofts et al., Birth Defects… Expand

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed